FAKTOR-OPTIONSSCHEIN - PACIRA BIOSCIENCES Stock

Certificat

DE000MG23D24

Market Closed - Börse Stuttgart 15:44:30 2024-05-17 EDT
11.57 EUR +10.72% Intraday chart for FAKTOR-OPTIONSSCHEIN - PACIRA BIOSCIENCES
Current month+86.61%
1 month+57.63%
Date Price Change
24-05-17 11.57 +10.72%
24-05-16 10.45 -9.45%
24-05-15 11.54 -6.26%
24-05-14 12.31 +12.32%
24-05-13 10.96 +13.58%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 03:44 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying PACIRA BIOSCIENCES, INC.
Issuer Morgan Stanley
WKN MG23D2
ISINDE000MG23D24
Date issued 2024-04-10
Strike 25.21 $
Maturity Unlimited
Parity 0.45 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 12.62
Lowest since issue 5.35
Spread 0.22
Spread %1.88%

Company Profile

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
Sector
-
More about the company

Ratings for Pacira BioSciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Pacira BioSciences, Inc.

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
30.82 USD
Average target price
44.9 USD
Spread / Average Target
+45.68%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW